Top Health Tech Companies in NYC, NY (1,079)

Strong Revenue Growth: Top-line revenue is reported to have grown strongly on a multi-year basis through 2023, with additional indications of continued increases into 2025–2026. This provides the clearest quantitative signal of momentum for a private company with limited disclosures.

Market Expansion: The provider network and product footprint have broadened, including new launches such as programmatic access and a consumer health media offering alongside partnerships that extend reach. These moves show growth beyond core point-of-care screens into adjacent adtech and consumer channels.

Investor Backing & Capital Strength: Advent International’s 2025 agreement to acquire the company and continued investment signal substantial sponsor support for scaling. Such backing typically underwrites further network growth and product innovation.

Profitability: The company is described as privately held, profitable, and debt-free, indicating a solid financial base. This positioning supports continued investment without reliance on external financing.

Strong Revenue Growth: Revenue is reported above $1 billion with indications of year-over-year increases into 2024 and sustained scale into FY2025, while cloud segments are noted as expanding strongly. These signals point to ongoing top-line momentum.

Market Expansion: Operations span 28 countries with 38 offices serving customers in 80+ countries, alongside recent moves such as a dedicated public-sector subsidiary and added international presence. This footprint suggests continued geographic and channel growth.

Investor Backing & Capital Strength: Funding momentum is pronounced, with a $35M Series A (Mar 2025), $100M Series B (Sep 2025), and a $70M Series C (Sep 2026) bringing total capital to about $225M at a valuation above $500M. This pattern signals sustained investor appetite and a materially stronger capital position.

Strong Revenue Growth: Reporting indicates subscription revenue nearly quadrupled year over year to about $29M, while contracted revenue surpassed $60M. These figures point to rapid scaling of recurring and booked revenue.

Market Expansion: Commercial reach appears to be growing, with monitoring of roughly 40,000 residents across just over 500 senior-living communities and new deployments among named operators. Expanding partnerships and portfolio rollouts suggest a widening customer footprint.

Market Expansion: Patient reach rose from 22M in 2022 to 25M in 2023 and 50M by January 2025, alongside new wins such as Sanford Health and multiple physician groups adopting the platform. Kora was also adopted by 10 provider organizations within its first year, reinforcing broader commercial uptake.

Product Line Growth: Cedar expanded from payments/billing into affordability, AI support, and the Kora AI agent in 2025–26, later broadening into the multi‑agent Kora Platform. Additional launches like Cedar Cover extended capabilities into Medicaid enrollment, renewals, and denials resolution.

Innovation-Driven Growth: AI‑driven workflows are central, with Kora handling roughly 400,000 patient calls in its first year and continued rollout of Cedar Intelligence in 2026. Recognition and ongoing AI feature releases signal a strategy centered on technology-led growth in healthcare financial workflows.

Investor Backing & Capital Strength: Multiple large financings (e.g., a $65M Series C led by Goldman Sachs Alternatives) alongside additional facilities (such as a $35M Stifel debt facility and a $50M growth-capital commitment) indicate strong access to capital and confidence to scale. These transactions are explicitly framed as funding nationwide platform expansion and operational build-out.

Market Expansion: Deployments are described as spanning hundreds of communities across 26 states, with portfolio-wide rollouts such as Navion’s phased deployment across 47 communities and continued clinic/location openings in targeted markets. Expansion plans emphasize entering new geographies and broadening presence across the senior-care continuum.

Product Line Growth: The offering has broadened from a single workflow product into an integrated platform that includes AI-powered monitoring/fall management (Sage Detect), EHR-integrated tasking and labor tools, and skilled-nursing solutions. Expanded integrations with EHR systems (e.g., Yardi, ALIS, ECP, PointClickCare, August Health) further extend product scope and use cases.

Market Expansion: Geographic reach is described as nationwide through Medicare, with pages indicating coverage in 48 to all 50 states, signaling active expansion. State-by-state therapist listings and nationwide positioning reinforce a broad and growing footprint.

Product Line Growth: Service scope expanded from therapy for older adults to a broader platform that includes behavioral health, advocacy, wellness classes, mind exercises, and AI care agents. This indicates growth beyond the original core offering.

Strong Hiring & Retention: Headcount and hiring activity are depicted as rising quickly, with quarter-over-quarter increases reported by company intelligence trackers and ongoing recruiting across clinical and corporate roles. This workforce build-out supports scaling operations.

Strong Revenue Growth: Revenue is reported to have grown 4× in 2023, more than 300% in 2024, and then doubled again in 2025, indicating sustained acceleration. Company communications consistently point to multi‑year, triple‑digit expansion across successive periods.

Investor Backing & Capital Strength: Capital raised includes a $47M Series B in 2024 and a $72M Series C in 2025, bringing total funding to $162M. This level of financing from institutional and strategic investors signals ample resources to support scale.

Strategic Partnerships: Partnerships are described with 7–8 of the top 10 U.S. life insurers and additional organizations such as Prudential, Principal, and Aflac. This enterprise-led distribution has extended access to tens of millions of policyholders and employees.

Investor Backing & Capital Strength: Funding is described as including a $30M Series B led by Andreessen Horowitz, bringing total backing to about $50M, signaling strong capital support for scaling. Investor commentary highlights conviction in Camber’s execution and claims-data advantage.

Market Expansion: Operations are reported to have broadened from an initial behavioral-health focus into additional care verticals and across all 50 states, alongside rising claims volume and provider reach. Company materials cite millions of claims processed and coverage of large billable amounts.

Strong Hiring & Retention: Hiring activity is ongoing, with the company described in the 51–200 employee range and noting its biggest hiring quarter in 2025. Open roles and expansion of enterprise go-to-market roles indicate continued team scaling.

Strong Revenue Growth: Revenue is depicted as rising dramatically, including an increase from $3.6M in 2021 to $617.4M in 2024 and subsequent commentary citing a roughly $1B run rate.

Investor Backing & Capital Strength: Capital access appears robust, highlighted by a $150M Series D in 2026 at an approximately $3B valuation and total funding near $328M from prominent investors.

Market Expansion: Geographic and channel reach is expanding, with 26,000+ clinicians across all 50 states, 125+ insurance partners (including Medicare and Medicaid), and movement into employer and health‑system partnerships.

Strong Revenue Growth: Revenue is rising at double-digit rates across recent periods, and management has increased full-year guidance, underscoring continued momentum. Growth is visible in both recent quarters and the prior year, indicating sustained top-line expansion.

Diversified Revenue Streams: Both Diagnostics and Data & Applications are expanding, with data-licensing/Insights activity increasing alongside clinical testing volumes. This mix reduces reliance on a single line of business and supports multiple growth vectors.

Strategic Partnerships: Collaborations with major biopharmaceutical companies and broader rollouts of platforms such as Next signal expanding commercial reach. Announced initiatives like a large whole‑genome dataset and work with firms including Merck reinforce external demand for the platform.

Strong Revenue Growth: ARR is reported to have surpassed $200M by June 2026 after crossing $100M in early 2025, with five consecutive years of 100% year-over-year growth. This consistent doubling signals rapid scaling at substantial revenue levels.

Investor Backing & Capital Strength: Funding rounds include $75M in 2024 at a valuation above $1B and a $250M Series E in 2025 at a reported $2.2B, with total capital raised cited at $400M+. Such late-stage financing and rising valuations indicate robust access to growth capital.

Strong Market Position & Advantage: Adoption is described as reaching roughly 1 in 6 U.S. apartments, with deep penetration among large property managers and hundreds of operators. Expansion into healthcare and notable distribution relationships have broadened its commercial footprint.

Investor Backing & Capital Strength: Capital access is depicted as strong, with a $32M Series A in 2024 followed by an oversubscribed $50M Series B in April 2025 that included $20M in credit. These rounds were led by institutional investors and were linked to observed traction.

Market Expansion: Reach is described at 15,000+ organizations and more than one million U.S. households, with targeting that now includes employers with 5,000–70,000+ eligible employees. Channel additions such as access to 25,000 employer groups via a PEO partner and mid‑market momentum further signal expanding distribution.

Strategic Partnerships: Ecosystem integration is broadening through relationships with TriNet, Workday Wellness, and PrismHR, alongside a Snowflake case study corroborating scale. These partnerships extend distribution and support enterprise penetration.

Investor Backing & Capital Strength: New capital in July 2026—$10M of a planned larger round with an SEC Form D filing—signals renewed financial support, with cumulative funding reported around $52.9M. This underpins ongoing rebuild and expansion efforts.

Market Expansion: Operations span Florida, Ohio, Michigan, Virginia, and Washington, with multiple local offices indicating a substantial multi-state footprint. Reported coverage of 45,000 attributed lives across multiple states points to meaningful scale in these markets.

Strong Hiring & Retention: Company materials and LinkedIn indicate a 201–500 employee range with active recruiting, including peer-support roles. Hiring activity in 2026 aligns with expansion across several states.

Market Expansion: Reported enrollments of roughly 250,000 in 2025 and a broker base exceeding 10,000 point to a rapidly widening operating footprint. AEP 2025 production metrics and tens of thousands of contracts processed further suggest the platform is scaling beyond its 2024 funding milestone.

Investor Backing & Capital Strength: A $25M Series B in January 2024, reportedly at a significant valuation step-up, underscores access to growth capital. Independent listings also record total funding in the high-$30Ms range, reinforcing external validation of capitalization.

Strong Hiring & Retention: Headcount reportedly expanded from around 40 to roughly 130 by 2025, and current postings include senior roles across revenue operations, engineering, product, and agent/customer experience. Active requisitions signal continued investment in growth infrastructure.

Strong Revenue Growth: Revenue increased from 2024 to 2025 and guidance points to another step‑up in 2026, signaling strong top‑line momentum tied to larger membership.

Market Expansion: The footprint expanded to 20 states for plan year 2026 and open‑enrollment selections reached about 3.4 million, indicating broader geographic reach and scale.

Strong Market Position & Advantage: After exits by peers, the company stands as an at‑scale, tech‑forward ACA carrier with material presence in key states such as Florida and Texas.